Analyst consensus rating
BeOne Medicines Analyst Rating: Strong Buy
ONC is rated Strong Buy by 27 analysts with a $433.02 target. As of 2026-08-24.
Direct answer
BeOne Medicines's consensus rating is Strong Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $433.02.
Forecast evidence checked August 24, 2026.
Get free BeOne Medicines email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $371.73
- Average price target
- $433.02
- High price target
- $528.00
- Low price target
- $370.00
- Low target gap
- -0.5%
- Target upside
- +16.5%
- High target gap
- +42%
- Target range width
- 42.5%
- Consensus rating
- Strong Buy
- Analysts
- 27
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BeOne Medicines?
BeOne Medicines has a verified Strong Buy consensus. The same dataset has an average price target of $433.02.
How far are BeOne Medicines's low and high targets from the recorded price?
The low target implies -0.5%, while the high target implies +42%.
How many analysts are included in BeOne Medicines's consensus?
The verified consensus includes 27 analysts.
How is BeOne Medicines's target upside or downside calculated?
The average target of $433.02 is divided by the recorded price of $371.73, then one is subtracted to produce +16.5%. This does not guarantee a future return.
When was BeOne Medicines's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.